Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Boston Common Asset Management LLC

Boston Common Asset Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,818 shares of the biopharmaceutical company’s stock after selling 7,258 shares during the period. Boston Common Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $15,542,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Adirondack Trust Co. grew its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 10 shares during the period. UMB Bank n.a. grew its position in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares during the period. Trust Co. of Vermont raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares during the period. Brighton Jones LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 14 shares during the period. Finally, Nvwm LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on REGN shares. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Up 0.7 %

Shares of REGN traded up $5.08 during midday trading on Friday, hitting $698.31. The company had a trading volume of 102,011 shares, compared to its average volume of 777,948. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company’s 50 day moving average price is $744.16 and its 200 day moving average price is $954.41. The stock has a market cap of $76.74 billion, a price-to-earnings ratio of 17.28, a PEG ratio of 1.60 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.